CAS NO: | 223488-57-1 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Molecular Weight (MW) | 468.57 |
---|---|
Formula | C25H28N2O5S |
CAS No. | 223488-57-1 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: ≥ 32 mg/mL |
Water: N/A | |
Ethanol: N/A | |
SMILES Code | O=C(O)COC1=CC=CC(CN(CC2=CC=C(C(C)(C)C)C=C2)S(=O)(C3=CC=CN=C3)=O)=C1 |
Synonym | Evatanepag; CP-533536; CP 533536; CP533536; Chemical Name: 2-(3-((N-(4-(tert-butyl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid |
In Vitro | In vitro activity: Evatanepag (formerly known as CP-533536) is a potent and selective agonist of EP2 receptor prostaglandin E2 (PGE2). It induces local bone formation with EC50 of 0.3 nM. C Kinase Assay: Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets. |
---|---|
In Vivo | P-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets. |
Animal model | Rats |
Formulation & Dosage | Administered locally as a single dose |
References | Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. |